➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Medtronic
Express Scripts
Johnson and Johnson
Dow

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ganetespib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Ganetespib?

Ganetespib is an investigational drug.

There have been 31 clinical trials for Ganetespib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., National Cancer Institute (NCI), and Dana-Farber Cancer Institute.

There are twenty-two US patents protecting this investigational drug and three hundred and sixty-nine international patents.

Recent Clinical Trials for Ganetespib
TitleSponsorPhase
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerEuropean CommissionPhase 2
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerUniversitaire Ziekenhuizen LeuvenPhase 2
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerUniversity of ChicagoN/A

See all Ganetespib clinical trials

Clinical Trial Summary for Ganetespib

Top disease conditions for Ganetespib
Top clinical trial sponsors for Ganetespib

See all Ganetespib clinical trials

US Patents for Ganetespib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganetespib   Start Trial Resorcinol derivative as HSP90 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN)   Start Trial
Ganetespib   Start Trial Pyrimidine-diamine dual HSP90/TRAP1 inhibitors Calasia Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Ganetespib   Start Trial Block copolymer conjugate of physiologically active substance Nippon Kayaku Kabushiki Kaisha (Tokyo, JP)   Start Trial
Ganetespib   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
Ganetespib   Start Trial Triazole compounds that modulate Hsp90 activity Synta Pharmaceuticals Corp. (Lexington, MA)   Start Trial
Ganetespib   Start Trial Method for treating proliferative disorders with HSP90 inhibitors Synta Pharmaceuticals Corp. (Lexington, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganetespib

Drugname Country Document Number Estimated Expiration Related US Patent
Ganetespib Australia 2016208863 2035-01-22   Start Trial
Ganetespib Canada 2974756 2035-01-22   Start Trial
Ganetespib China 107108591 2035-01-22   Start Trial
Ganetespib European Patent Office 3248968 2035-01-22   Start Trial
Ganetespib Japan 2018504413 2035-01-22   Start Trial
Ganetespib South Korea 20170113586 2035-01-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Express Scripts
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.